Time dependent transition of the levels of protein-conjugated acrolein (PC-Acro), IL-6 and CRP in plasma during stroke

Igarashi, 2010, Modulation of cellular function by polyamines, Int J Biochem Cell Biol, 42, 39, 10.1016/j.biocel.2009.07.009 Igarashi, 2015, Modulation of protein synthesis by polyamines, IUBMB Life, 67, 160, 10.1002/iub.1363 Igarashi, 2011, Protein-conjugated acrolein as a biochemical marker of brain infarction, Mol Nutr Food Res, 55, 1332, 10.1002/mnfr.201100068 Pegg, 2013, Toxicity of polyamines and their metabolic products, Chem Res Toxicol, 26, 1782, 10.1021/tx400316s Sakata, 2003, Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients, Biochem Biophys Res Commun, 305, 143, 10.1016/S0006-291X(03)00716-2 Tomitori, 2005, Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke, Stroke, 36, 2609, 10.1161/01.STR.0000190004.36793.2d Saiki, 2009, Intense correlation between brain infarction and protein-conjugated acrolein, Stroke, 40, 3356, 10.1161/STROKEAHA.109.553248 Giorgio, 2007, Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?, Nat Rev Mol Cell Biol, 8, 722, 10.1038/nrm2240 Sharmin, 2001, Polyamine cytotoxicity in the presence of bovine serum amine oxidase, Biochem Biophys Res Commun, 282, 228, 10.1006/bbrc.2001.4569 Yoshida, 2009, Acrolein toxicity: comparison with reactive oxygen species, Biochem Biophys Res Commun, 378, 313, 10.1016/j.bbrc.2008.11.054 Waragai, 2012, Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease, J Alzheimers Dis, 32, 33, 10.3233/JAD-2012-120253 Kobayashi, 1997, Subcortical silent brain infarction as a risk factor for clinical stroke, Stroke, 28, 1932, 10.1161/01.STR.28.10.1932 Vermeer, 2003, Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study, Stroke, 34, 1126, 10.1161/01.STR.0000068408.82115.D2 Vermeer, 2007, Silent brain infarcts: a systematic review, Lancet Neurol, 6, 611, 10.1016/S1474-4422(07)70170-9 Lopez, 2003, Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2, Arch Neurol, 60, 1394, 10.1001/archneur.60.10.1394 O'Leary, 1999, Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults, Cardiovascular Health Study Collaborative Research Group N Engl J Med, 340, 14 Inoue, 2007, Increased intima media thickness and atherosclerotic plaques in the carotid artery as risk factors for silent brain infarcts, J Stroke Cerebrovasc Dis, 16, 14, 10.1016/j.jstrokecerebrovasdis.2006.08.001 Bokura, 2006, Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study, J Stroke Cerebrovasc Dis, 15, 57, 10.1016/j.jstrokecerebrovasdis.2005.11.001 Yoshida, 2010, Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP, Atherosclerosis, 211, 475, 10.1016/j.atherosclerosis.2010.03.031 Saiki, 2013, Acrolein stimulates the synthesis of IL-6 and C-reactive protein (CRP) in thrombosis model mice and cultured cells, J Neurochem, 127, 652, 10.1111/jnc.12336 Shinohara, 2009, Postpublication external review of the Japanese guidelines for the management of stroke 2004, Stroke, 40, 1439, 10.1161/STROKEAHA.108.535070 Uchida, 1998, Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins, J Biol Chem, 273, 16058, 10.1074/jbc.273.26.16058 Broderick, 1993, Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality, Stroke, 24, 987, 10.1161/01.STR.24.7.987 Brott, 1989, Measurements of acute cerebral infarction: a clinical examination scale, Stroke, 20, 864, 10.1161/01.STR.20.7.864 Shinohara, 2006, Modified Rankin scale with expanded guidance scheme and interview questionnaire: interrater agreement and reproducibility of assessment, Cerebrovasc Dis, 21, 271, 10.1159/000091226 Jennett, 1975, Assessment of outcome after severe brain damage, Lancet, 1, 480, 10.1016/S0140-6736(75)92830-5 Benjamini, 1995, Controling the false discovery rate: a practical and powerful approach to multiple testing, J Roy Statist Soc Ser B (Methodological), 57, 289 Waje-Andreassen, 2005, IL-6: an early marker for outcome in acute ischemic stroke, Acta Neurol Scand, 111, 360, 10.1111/j.1600-0404.2005.00416.x Worthmann, 2010, The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome, Cerebrovasc Dis, 30, 85, 10.1159/000314624 Shenhar-Tsarfaty, 2010, Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack, Int J Stroke, 5, 16, 10.1111/j.1747-4949.2009.00396.x Lampl, 1990, Cerebrospinal fluid lactate dehydrogenase levels in early stroke and transient ischemic attacks, Stroke, 21, 854, 10.1161/01.STR.21.6.854 Yoshida, 2009, Acrolein, IL-6 and CRP as markers of silent brain infarction, Atherosclerosis, 203, 557, 10.1016/j.atherosclerosis.2008.07.022 Chen, 2005, Hypoadiponectinemia is associated with ischemic cerebrovascular disease, Arterioscler Thromb Vasc Biol, 25, 821, 10.1161/01.ATV.0000157784.25920.a7 Soderberg, 2004, Leptin, but not adiponectin, predicts stroke in males, J Intern Med, 256, 128, 10.1111/j.1365-2796.2004.01351.x